Does angiotensin receptor blocker use influence gastro-oesophageal cancer survival?

  • Aliment. Pharmacol. Ther

  • from Sarfaroj Khan
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.
Takeaway
  • Cancer-specific mortality was found to be moderately reduced in patients with gastro-oesophageal cancer using angiotensin receptor blockers (ARBs).
Why this matters
  • In England, ARBs are recommended as a first-line pharmacological treatment for hypertension patients aged under 55 y or with comorbid diabetes.
  • In-vitro models at various cancer sites have shown that ARBs reduce tumour growth, stimulate cell apoptosis, reduce metastasis, and inhibit angiogenesis.
Study design
  • This cohort study evaluated 5124 patients (ARB users, n=360; non-users, n=4764) with gastro-oesophageal cancer between 1998 and 2012.
  • Association between post-diagnosis ARB use and gastro-oesophageal cancer mortality was evaluated.
  • Funding: Clinical Research Bursary for AS from Cancer Research-UK.
Key results
  • Median follow-up duration was 1.4 y.
  • 3345 patients died during the follow-up period because of gastro-oesophageal cancer.
  • ARB users showed moderately reduced risk for gastro-oesophageal cancer mortality after adjustment (HR, 0.83) vs non-users.
  • Mortality rate was found to be significantly lower among patients receiving ARBs for at least 2 y (HR, 0.42; P-value for trend=.003).
  • Dose-response relationship showed slightly stronger association among patients with gastric cancer (aHR, 0.79) vs oesophageal cancer (aHR, 0.89).
Limitations
  • Cancer-specific deaths were not identifiable.